HCB 101
Alternative Names: HCB-101; HLX-701; SIRPα-Fc fusion protein - HanchorBioLatest Information Update: 26 Aug 2025
At a glance
- Originator HanchorBio
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Solid tumours
- Phase I/II Non-small cell lung cancer
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 01 Aug 2025 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Recurrent, Metastatic disease) in Taiwan (IV) (NCT07136545)
- 01 Jul 2025 HCB-101 licensed to Shanghai Henlius Biotech in Greater China (including Mainland China, Hong Kong, and Macau), Middle East and North Africa
- 01 Jul 2025 Phase-II clinical trials in Haematological malignancies in China (IV) prior to July 2025